Anti-Flt3/CD135 Monoclonal Antibody for FC, ELISA - P36888

Core Product Specifications and Parameters

Biological Background: FLT3 Function and Localization

• FLT3 (Fms-like tyrosine kinase 3), also known as CD135, FLK2, STK1, is a receptor-type tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG, playing a central role in the regulation of differentiation, proliferation, and survival of hematopoietic progenitor cells and dendritic cells.
• Upon ligand binding, FLT3 activates multiple downstream signaling pathways, including phosphorylation of SHC1 and AKT1, activation of mTOR, RAS signaling, and MAPK/ERK cascades, thereby promoting cell growth and inhibiting apoptosis.
• FLT3 is a member of the class III receptor tyrosine kinase family, characterized by an extracellular region with five immunoglobulin-like domains, a single transmembrane helix, and an intracellular kinase domain; alternative splicing generates isoforms with distinct properties.
• Subcellularly, FLT3 localizes primarily to the plasma membrane, with detection also in the endoplasmic reticulum lumen, consistent with its biosynthesis and membrane trafficking.
• Post-translational modifications include glycosylation, phosphorylation, and ubiquitin conjugation, which regulate its activity, stability, and signaling output; mutations causing constitutive activation are linked to acute myeloid leukemia (AML).
• Tissue expression is prominent in bone marrow, particularly in hematopoietic stem cells, myeloid progenitors, and granulocyte/macrophage progenitors; it is also detected in liver, thymus, spleen, lymph node, and at lower levels in kidney and pancreas, with high expression in T-cell leukemia.

Experimental Guidance and Technical Tips

• The immunogen spans the N-terminal extracellular domain (amino acids 27–163), suggesting that this monoclonal antibody may recognize the native extracellular epitope, making it potentially suitable for flow cytometry (FC) to detect cell surface FLT3.
• For ELISA applications, it is advisable to pair this antibody with a validated detection antibody to establish a sensitive sandwich ELISA; optimal working concentrations should be experimentally determined for each assay system.
• Given FLT3’s glycosylation and potential dimerization, denaturing western blotting may require careful optimization; molecular weight variants (108 and 113 kDa) reflect differential glycosylation or precursor forms.
• The antibody is specific to human FLT3; cross-reactivity with other species or with other receptor tyrosine kinases should be independently verified in the relevant sample matrix.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is your comprehensive sourcing partner for high-quality IVD raw materials, supporting diagnostic manufacturers, laboratories, and research institutes worldwide. This anti-FLT3 monoclonal antibody exemplifies our capability to provide critical immunological reagents for hematological malignancy research and diagnostic development. Beyond single antibodies, we offer validated antibody pairs, bulk ancillary reagents, and expert technical consulting—ensuring you have a reliable supply chain from concept to clinic.